Evidence map›Paper›PMID 30400954›Full record

ArticleJournal of experimental & clinical cancer research : CR2018

Vitexin compound 1, a novel extraction from a Chinese herb, suppresses melanoma cell growth through DNA damage by increasing ROS levels.

Nian Liu, Kuan Song Wang, Min Qi, Ying Jun Zhou, Guang Yao Zeng, Juan Tao, Jian Da Zhou, Jiang Lin Zhang, Xiang Chen, Cong Peng

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
12.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 75 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Flavonoids extract fromWorld journal of experimental medicine · 2025
    Review
  7. Review
  8. Molecular Mechanisms of Vitexin: An Update on Its Anti-Cancer Functions.International journal of molecular sciences · 2025
    Review
  9. Anti-proliferative Activity ofArchives of Razi Institute · 2024
    Article
  10. Combination ofFrontiers in pharmacology · 2024
    Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Nian LiuDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Kuan Song WangDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Min QiDepartment of Plastic and Cosmetic Surgery, XiangYa Hospital, Central South University, Changsha, Hunan, China.
Ying Jun ZhouSchool of Pharmaceutical Science,Central, South University, Changsha, Hunan, China.
Guang Yao ZengSchool of Pharmaceutical Science,Central, South University, Changsha, Hunan, China.
Juan TaoDepartment of Dermatology, Affiliated Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Jian Da ZhouDepartment of Plastic Surgery of Third Xiangya Hospital, Central South University, Changsha, China.
Jiang Lin ZhangDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China. leozjl1010@126.com.
Xiang ChenDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China. chenxiangck@gmail.com.
Cong PengDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China. pengcongxy@csu.edu.cn.
Central South University · CNHunan Cancer Hospital · CNXiangya Hospital Central South University · CNUnion Hospital · CN

Funding

National Natural Science Foundation of China 81472852National Natural Science Foundation of China 81572679National Natural Science Foundation of China 81772917
6 · The paper itself

Abstract

backgroundVitex negundo L (Verbenaceae) is an aromatic shrub that is abundant in Asian countries. A series of compounds from Vitex negundo have been used in traditional Chinese medicine for the treatment of various diseases. Cutaneous melanoma is one of the most aggressive malignancies. A significant feature of melanoma is its resistance to traditional chemotherapy and radiotherapy; therefore, there is an urgent need to develop novel treatments for melanoma.

methodsWe first examined the effects of VB1 (vitexin compound 1) on cell viability by CCK-8 (cell counting kit) and Colony Formation Assay; And then, we analyzed the apoptosis and cell cycle by flow cytometry, verified apoptosis by Immunoblotting. The in vivo effect of VB1 was evaluated in xenograft mouse model. Potential mechanisms of VB1's antitumor effects were explored by RNA sequencing and the key differential expression genes were validated by real-time quantitative PCR. Finally, the intracellular reactive oxygen species (ROS) level was detected by flow cytometry, and the DNA damage was revealed by Immunofluorescence and Immunoblotting.

resultsIn this study, we show that VB1, which is a compound purified from the seed of the Chinese herb Vitex negundo, blocks melanoma cells growth in vitro and in vivo, arrests the cell cycle in G2/M phase and induces apoptosis in melanoma cell lines, whereas the effects are not significantly observed in normal cells. To study the details of VB1, we analyzed the alteration of gene expression profiles after treatment with VB1 in melanoma cells. The findings showed that VB1 can affect various pathways, including p53, apoptosis and the cell cycle pathway, in a variety of melanoma cell lines. Furthermore, we confirmed that VB1 restored the P53 pathway protein level, and then we demonstrated that VB1 significantly induced the accumulation of ROS, which resulted in DNA damage in melanoma cell lines. Interestingly, our results showed that VB1 also increased the ROS levels in BRAFi (BRAF inhibitor)-resistant melanoma cells, leading to DNA cytotoxicity, which caused G2/M phase arrest and apoptosis.

conclusionsTaken together, our findings indicate that vitexin compound 1 might be a promising therapeutic Chinese medicine for melanoma treatment regardless of BRAFi resistance.

Indexed as

AnimalsApigeninApoptosisCell Line, TumorDNA DamageDrugs, Chinese HerbalFemaleHumansMelanomaMiceMice, Inbred BALB CMice, NudeReactive Oxygen SpeciesApigeninDrugs, Chinese HerbalReactive Oxygen SpeciesvitexinDNA damageMelanomaROSVitexin compound 1

Identifiers

PMID30400954
PMCPMC6219156
OpenAlexW2899654358

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.